Our Science
One tunable technology platform for ultra-sustained, controlled and targeted pain relief
Allay is overturning the current pain relief paradigm by developing products to support patients with their pain through every phase of recuperation and help them on the path to recovering normal function. We aim to provide pain relief to patients when they most need it, and over an extended period of time to match their recovery.
Our proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates that deliver pain relief within a targeted site over weeks rather than days: an order of magnitude greater than the longest-lasting pain treatments currently available.
Cyclic pain such as that caused by gout comes and goes at predictable times. Allay’s platform can be tuned to deliver pain relief in pre-set waves over an extended duration.
Cyclic pain such as that caused by gout comes and goes at predictable times. Allay’s platform can be tuned to deliver pain relief in pre-set waves over an extended duration.
Cyclic pain such as that caused by gout comes and goes at predictable times. Allay’s platform can be tuned to deliver pain relief in pre-set waves over an extended duration.
Chronic pain such as that caused by osteoarthritis is constant and requires ongoing management. Allay’s platform can be tuned to deliver pain relief at a constant level over an extended duration.
Chronic pain such as that caused by osteoarthritis is constant and requires ongoing management. Allay’s platform can be tuned to deliver pain relief at a constant level over an extended duration.
Chronic pain such as that caused by osteoarthritis is constant and requires ongoing management. Allay’s platform can be tuned to deliver pain relief at a constant level over an extended duration.
Post-surgical pain is significant in the short-term but gradually reduces as the injury heals. Allay’s platform can match this journey with immediate, high levels of pain relief that reduces over weeks to ease recuperation.
Post-surgical pain is significant in the short-term but gradually reduces as the injury heals. Allay’s platform can match this journey with immediate, high levels of pain relief that reduces over weeks to ease recuperation.
Post-surgical pain is significant in the short-term but gradually reduces as the injury heals. Allay’s platform can match this journey with immediate, high levels of pain relief that reduces over weeks to ease recuperation.
Highly tunable results. Our drug-biopolymer architecture can be designed for a variety of potential indications through tuning its analgesic release profile and rate.
Pain management innovation has stagnated for decades, and incremental improvements have not yet delivered a product that provides more than several days of pain relief. But millions of surgeries every year result in post-surgical recuperation and rehabilitation that often takes weeks or months. This means that pain management during this period currently often involves constant re-dosing, clinical oversight and the use of systemic analgesics with major drawbacks – such as with opioids.
Opioids: systemic analgesics with
major drawbacks
Systemic analgesics such as opioids create systemic side effects including the significant risk of
abuse and addiction, which have fueled a major health crisis in the United States and beyond.
Blunt approach: Opioids act directly on the central nervous system (CNS) to mask the sensation of pain – they are not targeted to the actual source of pain.
Systemic side effects: Opioids’ systemic action on the CNS brings a range of neurological and physiological side effects including nausea, constipation, drowsiness, respiratory depression and the risk of dependence. This creates extra risks for the patient which must be managed.
Fuel ongoing health crisis: The opioid epidemic has devastated lives and families across the United States and places a major burden on society and healthcare systems. This has created an urgent, ongoing need for differentiated pain solutions that contribute to reduced use of opioids.
Short-term action: The effects of opioids do not last long, and repeated use often leads to tolerance and a heightened risk of dependence.
Our Solution: Local analgesia that
Stays For The Whole Journey
A highly tunable drug-biopolymer ‘architecture’ that holds and releases high densities of drug over time in a predictable and controlled way
Platform Features
Allay believes an era of short-term pain management is over. We were founded around the first technology platform that could deliver the major features needed to ensure long-lasting local pain relief.
These features include:
- Our drug-biopolymer architecture can be tuned to release drugs at the desired rate – from hours to weeks, allowing a wide range of potential therapeutic profiles.
- The rate of release occurs with ‘first order kinetics’: moving from highest exposure post-surgery to gradually reduce over time, aligning with the general trajectory of a patient’s natural recovery.
- The amount of drug and its rate of release are adjusted through changes to the drug-biopolymer configuration and our proprietary manufacturing process.
- Our product candidates are designed to treat pain in a highly targeted way – we treat pain at its source, avoiding the side-effects of a blanket systemic approach like opioids.
- We only incorporate validated local analgesics into our candidates, leveraging decades of supportive safety data and a proven high therapeutic index.
- Our platform is uniquely capable of incorporating high densities of analgesic, essential when working within the close confines of a surgical site.
- This capacity supports a wide range of dosages and configurations over an extended time period.
- After delivering therapeutic benefit, Allay’s product candidates are designed to naturally degrade into water and carbon dioxide over time and disappear from the body.